公开(公告)号：US10758511B2

公开(公告)日：2020-09-01

申请号：US15777141

申请日：2016-11-17

申请人： Massachusetts Eye and Ear Infirmary ,  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

发明人： Kip M. Connor ,  Eiichi Hasegawa ,  Bruce D. Hammock ,  Kin Sing Stephen Lee

IPC分类号： A61K31/17 ,  A61K31/202 ,  A61K31/336 ,  A61K31/445 ,  A61K31/4468 ,  A61P27/02 ,  A61P27/04 ,  A61P27/06 ,  A61K9/00

摘要： This disclosure relates to methods of reducing inflammation, angiogenesis, vascular leakage and neovascularization by administering to a subject in need thereof one or more stable analogs of CYP450 lipid metabolites (e.g., eicosanoids) and one or more inhibitors of a soluble epoxide hydrolase (sEH). This disclosure also relates to methods of treating disorders associated with inflammation, angiogenesis, vascular leakage and neovascularization by administering to a subject in need thereof one or more stable analogs of CYP450 lipid metabolites (e.g., eicosanoids) and one or more inhibitors of a soluble epoxide hydrolase (sEH). This disclosure further relates to pharmaceutical compositions and kits comprising at least one stable analog of CYP450 lipid metabolites (e.g., eicosanoids) and at least one inhibitor of a soluble epoxide hydrolase (sEH).

公开(公告)号：US20180325860A1

公开(公告)日：2018-11-15

申请号：US15777141

申请日：2016-11-17

申请人： Kip M. CONNOR ,  Eiichi HASEGAWA ,  Bruce D. HAMMOCK ,  Kin Sing Stephen LEE ,  Massachusetts Eye and Ear Infirmary ,  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

发明人： Kip M. Connor ,  Eiichi Hasegawa ,  Bruce D. Hammock ,  Kin Sing Stephen Lee

IPC分类号： A61K31/336 ,  A61K9/00 ,  A61P27/06

CPC分类号： A61K31/336 ,  A61K9/0019 ,  A61K9/0048 ,  A61K31/17 ,  A61K31/202 ,  A61K31/445 ,  A61K31/4468 ,  A61K2300/00 ,  A61P27/02 ,  A61P27/04 ,  A61P27/06

摘要： This disclosure relates to methods of reducing inflammation, angiogenesis, vascular leakage and neovascularization by administering to a subject in need thereof one or more stable analogs of CYP450 lipid metabolites (e.g., eicosanoids) and one or more inhibitors of a soluble epoxide hydrolase (sEH). This disclosure also relates to methods of treating disorders associated with inflammation, angiogenesis, vascular leakage and neovascularization by administering to a subject in need thereof one or more stable analogs of CYP450 lipid metabolites (e.g., eicosanoids) and one or more inhibitors of a soluble epoxide hydrolase (sEH). This disclosure further relates to pharmaceutical compositions and kits comprising at least one stable analog of CYP450 lipid metabolites (e.g., eicosanoids) and at least one inhibitor of a soluble epoxide hydrolase (sEH).